Longitudinal changes in placental biomarkers in women with early versus late placental dysfunction

Hypertens Pregnancy. 2019 Nov;38(4):268-277. doi: 10.1080/10641955.2019.1668948. Epub 2019 Sep 27.

Abstract

Objective: To evaluate longitudinal changes of angiogenic biomarkers in early- (EO-PD) versus late-onset (LO-PD) placental dysfunction. Methods: Serum PlGF and sFlt-1 measured at different intervals in EO-PD (n= 43), LO-PD (n= 31) and controls (n = 133). Results: sFlt-1/PlGF ratio was higher at 16 weeks (30.6 vs 17.5), 20 weeks (29.3 vs 8.9) and 30 weeks (16.6 vs 6.7) in EO-PD vs controls (all p< 0.05), but not in LO-PD. Longitudinal changes for all intervals had higher AUC than single measurements. Conclusion: Longitudinal biomarker change between 12 and 30 weeks could improve prediction of EO-PD compared to single measurements.

Keywords: Early Pregnancy Complications; Eclampsia; Fetal Growth Restriction; HELLP; High-Risk Pregnancy; Placenta; Preeclampsia; Pregnancy induced Hypertension.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biomarkers / blood
  • Female
  • Humans
  • Placenta Diseases / blood*
  • Placenta Growth Factor / blood*
  • Pregnancy
  • Pregnancy Trimesters / blood*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor Receptor-1 / blood*

Substances

  • Biomarkers
  • PGF protein, human
  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1